Eli Lilly Announces 800-Person Sales Force Expansion for Tirzepatide Franchise
By FieldPulse Editorial · February 4, 2026
Tags: sales-force, glp-1, hiring
Eli Lilly is adding 800 sales reps to its tirzepatide field organization, one of the largest single-year pharma expansions in recent memory.
Eli Lilly confirmed in a Q1 2026 investor briefing that it is adding approximately 800 field representatives across its Mounjaro and Zepbound commercial organizations, representing one of the largest single-year sales force expansions in the company's history.
The expansion is driven by persistent demand that has outpaced detailing capacity in primary care and endocrinology call points.
Lilly cited research showing that rep-visited accounts are converting at 2.4x the rate of undetailed accounts, even in markets where awareness of tirzepatide is high.
The build includes new primary care territory roles, a dedicated obesity specialist team targeting high-volume weight management clinics, and an expanded payer access support function.
Lilly is also standing up a second-tier field medical affairs team to handle the volume of clinical queries generated by GLP-1 expansion into new indications including sleep apnea and cardiovascular risk reduction.
For existing Lilly reps, the territory compression that will result from adding 800 headcount is expected to reduce average territory size by 18%, concentrating effort on higher-potential accounts.
Field leadership confirmed that quota structures will be recalibrated in Q2 to reflect the new territory footprints.
The hiring push comes as Novo Nordisk faces continued manufacturing constraints on Wegovy, giving Lilly a window to build durable prescriber relationships with the expanded workforce.